Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)
- 1 March 2013
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 42 (2), 348-352
- https://doi.org/10.1097/mpa.0b013e31825c53fa
Abstract
Gastroenteropancreatic neuroendocrine tumors (NETs) are rare tumors of the endocrine and nervous systems. Whereas early surgical resection can significantly reduce tumor mass, there are few data available concerning the control of hormonal secretion and associated symptoms. Studies have shown that the tyrosine kinase inhibitor sunitinib significantly prolongs progression-free survival in patients with pancreatic NETs. Here, we present 2 case reports of sunitinib in patients with different types of NETs. The patients were a 12-year-old boy with metastatic vasoactive intestinal polypeptide-producing tumor (VIPoma) and a 70-year-old woman with metastatic paraganglioma/NET. Both were treated in an outpatient clinical setting. Sunitinib was titrated to 37.5 mg on a continuous daily dosing schedule in the patient with VIPoma, and the dose was 50 mg/d (4 weeks on, 2 weeks off) in the patient with the paraganglioma/NET. The patient with the paraganglioma/NET had a confirmed complete radiographic response and the patient with VIPoma had a confirmed partial response (Response Evaluation Criteria in Solid Tumors). In both patients, improvements were observed in biochemical tumor markers, clinical responses, and quality of life. In these patients, sunitinib reduced biochemical markers and stabilized or reduced tumor bulk and may therefore be a potential therapeutic option for these tumor types.Keywords
This publication has 29 references indexed in Scilit:
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 2010
- The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine TumorsPancreas, 2010
- Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumorsEndocrine-Related Cancer, 2008
- Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumoursGut, 2006
- ADMINISTRATION OF SOMATOSTATIN ANALOG (SMS 201–995) IN THE TREATMENT OF A FISTULA OCCURRING AFTER PANCREAS TRANSPLANTATIONTransplantation, 1987
- Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromesAmerican Journal Of Medicine, 1986
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970
- Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemiaAmerican Journal Of Medicine, 1958